{"name":"Oncotherapeutics","slug":"oncotherapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ruxolitinib Oral Tablet [Jakafi]","genericName":"Ruxolitinib Oral Tablet [Jakafi]","slug":"ruxolitinib-oral-tablet-jakafi","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Ruxolitinib Oral Tablet [Jakafi]","genericName":"Ruxolitinib Oral Tablet [Jakafi]","slug":"ruxolitinib-oral-tablet-jakafi","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE13eHdkZjlSR0Ztc3o4M3BSazRmUG5rdVVad0hLNjRLVnRaRlBJdklFc2JVSlE5ZjdJOVd6TEY1OFd2bU5RWU05WFcyWkNNWWdmWks2X1l0RWNyS1VKaXF1TWhnQW5GemhEeHVvSA?oc=5","date":"2025-10-13","type":"pipeline","source":"Oncodaily","summary":"From Cancer Manhattan Project to Quantum Oncotherapeutics and Nowadays Bioshield - The New Promise in Oncology - Oncodaily","headline":"From Cancer Manhattan Project to Quantum Oncotherapeutics and Nowadays Bioshield - The New Promise in Oncology","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-27","type":"trial","source":"expresspharma.in","summary":"Lupin announces presentation of phase 1 data on LNP7457 (PRMT5 inhibitor) at the ASCO - Annual Meeting 2025 - expresspharma.in","headline":"Lupin announces presentation of phase 1 data on LNP7457 (PRMT5 inhibitor) at the ASCO - Annual Meeting 2025","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}